No Yes Ok

Archive

EQT Life Sciences’ portfolio company Cardior Pharmaceuticals to be acquired by Novo Nordisk Monday, March 25th, 2024
  Acquisition values Cardior Pharmaceuticals (“Cardior”) at up to EUR 1.025 billion, including an upfront payment and additional payments if certain development and commercial milestones are achieved [...]
EQT Life Sciences portfolio company Amolyt Pharma to be acquired by AstraZeneca for up to USD 1.05 billion Thursday, March 14th, 2024
EQT Life Sciences has supported Amolyt since its first investment in 2019, during which the company went from preclinical stages to running a Phase III    The transaction is expected to close in the third q [...]
EQT Life Sciences Leads Tubulis’ Upsized €128 Million Series B2 Financing Thursday, March 14th, 2024
Financing round co-led by EQT Life Sciences and Nextech Invest1, with participation from other leading global biotechnology investors Proceeds will be used to advance clinical trials of lead solid tumor targete [...]
EQT Life Sciences leads €30M Series C funding round in Onera Wednesday, March 13th, 2024
Onera Health, a leader in sleep diagnostic and monitoring solutions, closed a €30M ($32M) Series C financing round. The all-equity round was led by EQT Life Sciences and co-led by Gimv, with existing investors Innov [...]
EQT Life Sciences leads $42M funding round in Phagenesis Monday, March 4th, 2024
Phagenesis, a medical devices company, which specializes in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and co-led by Sectoral Asset Management [...]


2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

EQT Life Sciences’ portfolio company Cardior Pharmaceuticals to be acquired by Novo Nordisk Monday, March 25th, 2024
  Acquisition values Cardior Pharmaceuticals (“Cardior”) at up to EUR 1.025 billion, including an upfront payment and additional payments if certain development and commercial milestones are achieved [...]
EQT Life Sciences portfolio company Amolyt Pharma to be acquired by AstraZeneca for up to USD 1.05 billion Thursday, March 14th, 2024
EQT Life Sciences has supported Amolyt since its first investment in 2019, during which the company went from preclinical stages to running a Phase III    The transaction is expected to close in the third q [...]
EQT Life Sciences Leads Tubulis’ Upsized €128 Million Series B2 Financing Thursday, March 14th, 2024
Financing round co-led by EQT Life Sciences and Nextech Invest1, with participation from other leading global biotechnology investors Proceeds will be used to advance clinical trials of lead solid tumor targete [...]
EQT Life Sciences leads €30M Series C funding round in Onera Wednesday, March 13th, 2024
Onera Health, a leader in sleep diagnostic and monitoring solutions, closed a €30M ($32M) Series C financing round. The all-equity round was led by EQT Life Sciences and co-led by Gimv, with existing investors Innov [...]
EQT Life Sciences leads $42M funding round in Phagenesis Monday, March 4th, 2024
Phagenesis, a medical devices company, which specializes in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and co-led by Sectoral Asset Management [...]


2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund